Lia Tsimberidou, MD, PhD

Lia Tsimberidou, MD, PhD
 

Tenured Associate Professor
Department of Investigational Cancer Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX


How do you identify patients with targetable alterations that would suggest their triage into clinical trials?

How do you identify patients with targetable alterations that would suggest their triage into clinical trials?

Can you give us patient-specific examples that demonstrate the potential clinical benefits -- improvements in PFS, OS and other metrics -- of whole exome, hybrid capture-based NGS?

Can you give us patient-specific examples that demonstrate the potential clinical benefits — improvements in PFS, OS and other metrics — of whole exome, hybrid capture-based NGS?

Can you share a case history of a patient who was failing multiple, standard therapies and then responded to treatment based on NGS profiling?

Can you share a case history of a patient who was failing multiple, standard therapies and then responded to treatment based on NGS profiling?

Although you work in a tertiary cancer referral and research center where many patients have advanced disease, at what point in the natural history of cancer do you think is the ideal time to perform NGS?

Although you work in a tertiary cancer referral and research center where many patients have advanced disease, in general, at what point in the natural history of cancer do you think is the ideal time to perform NGS?

What is the risk of not performing comprehensive NGS molecular profiling, and relying exclusively on more targeted panels? What might we miss?

What is the risk of not performing comprehensive NGS molecular profiling, and relying exclusively on more targeted panels? What might we miss?